A Phase I, open label study of SIRPα antagonist (BI 770371) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors7
![NCT05327946 (1501-0001) NCT05327946 (1501-0001)](/inoncology/sites/default/files/2024-05/1501-0001_study_design.png)
AE, adverse event; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose; SIRPα, signal-regulatory protein alpha.